The Impact of Third-Hand E#Cigarette Exposure on Platelet Function and Thrombogenesis

三手电子的影响

基本信息

项目摘要

While smoking has been on the decline, e-cigarette usage has been on the rise; especially in vulnerable populations. Furthermore, even though the contribution of third-hand smoke (THS) and- more recently- e- cigarettes to the pathogenesis of thrombotic diseases was documented, the involvement of third-hand e- cigarettes (THEC) in such disease processes remains unknown. Consequently, the present application outlines studies that address fundamental, mechanistic, and clinically-relevant translational aspects of the adverse-health effects of THEC, in the context of thrombotic disease and platelet biology, and in a device-, e-liquid-, and sex- specific manner. These studies are of paramount significance given the “perceived safety” of e-cigarettes, and will be conducted using a novel/new THEC exposure model. The Aims of our proposal are: Aim 1. Investigate the impact of THEC exposure on platelet-dependent disease states. While there is compelling evidence that e-cigarettes do exert negative health effects, the impact of THEC on platelet-dependent diseases is still unknown. To address this issue, we will determine the consequences of THEC exposure on normal hemostasis and platelet counts. Subsequent studies will examine whether THEC participates in the development of thrombosis-based disease. Finally, we will determine the effects of THEC on plasma “markers” of thrombosis. Notably, our experiments will be designed in a manner that addresses the role of the device, and e-liquid in mediating the “platelet”-dependent negative effects of THEC. Furthermore, our preliminary data does show, for the first time, that THEC, THS and e-cigarettes increase the risk of thrombotic cardiovascular disease. Aim 2. Investigate the mechanism by which THEC exposure modulates platelet function. Even though our published data indicated that THS and e-cigarettes modulate platelet activation, whether THEC produces similar effects (i.e., the mechanism by which it modulates platelet function) remains to be investigated. Thus, the overall goal of the experiments proposed in this section is to determine the impact of THEC exposure on the various platelet functional responses (e.g., GPIIb-IIIa activation), thromboxane A2 levels, and on biochemical “markers” of platelet activation. It is noteworthy that our preliminary data shows that THEC does enhance platelet aggregation and secretion. Collectively, these experiments will make significant contributions to our understanding of the consequences of THEC/e-cigarettes on platelet activation and cardiovascular human health, and the mechanism by/through which it exerts these effects, in a device-, e-liquid-, and sex-specific manner.
虽然吸烟一直在下降,但电子烟的使用一直在上升;特别是在弱势群体中, 人口。此外,即使三手烟(THS)和最近的电子烟的贡献, 吸烟对血栓性疾病发病机制的影响,第三手电子烟的参与, 香烟(THEC)在这种疾病过程中的作用仍然未知。因此,本申请概述了 研究,解决基本的,机械的,临床相关的翻译方面的不良健康 在血栓性疾病和血小板生物学背景下,以及在器械、电子液体和性别中,THEC的作用 具体方式。考虑到电子烟的“感知安全性”,这些研究具有至关重要的意义, 将使用新的/新的THEC暴露模型进行。我们建议的目的是: 目标1。研究THEC暴露对血小板依赖性疾病状态的影响。虽然 令人信服的证据表明,电子烟确实会对健康产生负面影响,THEC对血小板依赖性 疾病仍然未知。为了解决这个问题,我们将确定THEC暴露于 止血和血小板计数正常其后的研究会探讨临市局有否参与 血栓形成性疾病的发展。最后,我们将确定THEC对血浆“标记物”的影响 血栓形成值得注意的是,我们的实验将以解决设备作用的方式设计, 电子液体介导THEC的“血小板”依赖性负面效应。此外,我们的初步数据显示, 首次表明,THEC,THS和电子烟会增加血栓性心血管疾病的风险。 目标二。研究THEC暴露调节血小板功能的机制。即使我们的 已发表的数据表明,THS和电子烟调节血小板活化,无论THEC是否产生类似的 效果(即,它调节血小板功能的机制)仍有待研究。因此, 本节中提出的实验的目的是确定THEC暴露对各种 血小板功能反应(例如,GPIIb-IIIa激活)、血栓素A2水平和生化“标志物” 血小板活化的迹象值得注意的是,我们的初步数据显示,THEC确实能增强血小板聚集, 聚集和分泌。 总的来说,这些实验将对我们理解 THEC/电子烟对血小板活化和人类心血管健康的影响,以及 它以装置、电子液体和性别特异性方式发挥这些作用的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Fatima Z. Alshbool其他文献

The Impact of Maternal/In Utero Exposure of Novel Tobacco Products on the Offspring Cardiovascular Health
  • DOI:
    10.1007/s12012-025-10023-5
  • 发表时间:
    2025-06-20
  • 期刊:
  • 影响因子:
    3.700
  • 作者:
    Shelby S. Umphres;Precious O. Badejo;Fadi T. Khasawneh;Fatima Z. Alshbool
  • 通讯作者:
    Fatima Z. Alshbool

Fatima Z. Alshbool的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Fatima Z. Alshbool', 18)}}的其他基金

The Impact of In Utero E-Cigarette Exposure on Platelet Function and Thrombogenesis
子宫内电子烟暴露对血小板功能和血栓形成的影响
  • 批准号:
    10373790
  • 财政年份:
    2022
  • 资助金额:
    $ 7.58万
  • 项目类别:
The Impact of In Utero E-Cigarette Exposure on Platelet Function and Thrombogenesis
子宫内电子烟暴露对血小板功能和血栓形成的影响
  • 批准号:
    10640062
  • 财政年份:
    2022
  • 资助金额:
    $ 7.58万
  • 项目类别:
Investigate the mechanism and impact of E-cigarettes on platelet function and thrombogenesis
研究电子烟对血小板功能和血栓形成的机制和影响
  • 批准号:
    10683785
  • 财政年份:
    2022
  • 资助金额:
    $ 7.58万
  • 项目类别:
The Impact of Third-Hand E#Cigarette Exposure on Platelet Function and Thrombogenesis
三手电子的影响
  • 批准号:
    10055289
  • 财政年份:
    2020
  • 资助金额:
    $ 7.58万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 7.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 7.58万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 7.58万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 7.58万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 7.58万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 7.58万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 7.58万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 7.58万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 7.58万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 7.58万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了